Cathie Wood's ARK Snaps Up Tempus AI Shares Despite Revenue Miss and Market Sell-Off

GuruFocus

01-14

Cathie Wood's ARK Investment Management adds to its stake in Tempus AI (TEM, Financial) after the stock tumbled nearly 14% on Monday, January 13 4:00 PM ET. The company announces preliminary fourth-quarter revenue projections that fall short of expectations, shaking investor confidence.

Tempus AI predicts $200 million in revenue for the quarter, missing analysts' estimates of $205.7 million. Even so, the number shows a 35% jump from the same period last year. CEO Eric Lefkofsky highlights strong growth in genomics revenue, up 30%, and data and services revenue, which climbs 45%. For the full year, revenue climbs 30% to approximately $693 million.ARK's Genomic Revolution ETF (ARKG, Financial) snaps up 379,000 shares during the sell-off, bringing its total holding in Tempus AI to over $47 million.

The position now accounts for 4.08% of the fund's portfolio. Other top names in the fund include Twist Bioscience (TWST, Financial), Recursion Pharmaceuticals (RXRX, Financial), and Crispr Therapeutics (CRSP, Financial).The purchase shows ARK's confidence in Tempus AI's potential as a leader in genomics and AI-driven healthcare innovation.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2503284165"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503284165\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503284165?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503284165","market":"us","top_or_hot":-1,"title":"Cathie Wood's ARK Snaps Up Tempus AI Shares Despite Revenue Miss and Market Sell-Off","media":"GuruFocus","content":"<html><body><div><div><p>Cathie Wood's ARK Investment Management adds to its stake in <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM, Financial) after the stock tumbled nearly 14% on Monday, January 13 4:00 PM ET. The company announces preliminary fourth-quarter revenue projections that fall short of expectations, shaking investor confidence.</p><p>Tempus AI predicts $200 million in revenue for the quarter, missing analysts' estimates of $205.7 million. Even so, the number shows a 35% jump from the same period last year. CEO Eric Lefkofsky highlights strong growth in genomics revenue, up 30%, and data and services revenue, which climbs 45%. For the full year, revenue climbs 30% to approximately $693 million.ARK's Genomic Revolution ETF (ARKG, Financial) snaps up 379,000 shares during the sell-off, bringing its total holding in Tempus AI to over $47 million. </p><p>The position now accounts for 4.08% of the fund's portfolio. Other top names in the fund include Twist Bioscience (TWST, Financial), Recursion Pharmaceuticals (RXRX, Financial), and Crispr <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CRSP, Financial).The purchase shows ARK's confidence in Tempus AI's potential as a leader in genomics and AI-driven healthcare innovation.</p></div></div></body></html>","source":"gurufocus_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Cathie Wood's ARK Snaps Up Tempus AI Shares Despite Revenue Miss and Market Sell-Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood's ARK Snaps Up Tempus AI Shares Despite Revenue Miss and Market Sell-Off\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">GuruFocus</strong><span class=\"h-time small\">2025-01-14 18:46</span>\n</p>\n</header>\n<article>\n<div><div><p>Cathie Wood's ARK Investment Management adds to its stake in <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM, Financial) after the stock tumbled nearly 14% on Monday, January 13 4:00 PM ET. The company announces preliminary fourth-quarter revenue projections that fall short of expectations, shaking investor confidence.</p><p>Tempus AI predicts $200 million in revenue for the quarter, missing analysts' estimates of $205.7 million. Even so, the number shows a 35% jump from the same period last year. CEO Eric Lefkofsky highlights strong growth in genomics revenue, up 30%, and data and services revenue, which climbs 45%. For the full year, revenue climbs 30% to approximately $693 million.ARK's Genomic Revolution ETF (ARKG, Financial) snaps up 379,000 shares during the sell-off, bringing its total holding in Tempus AI to over $47 million. </p><p>The position now accounts for 4.08% of the fund's portfolio. Other top names in the fund include Twist Bioscience (TWST, Financial), Recursion Pharmaceuticals (RXRX, Financial), and Crispr <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CRSP, Financial).The purchase shows ARK's confidence in Tempus AI's potential as a leader in genomics and AI-driven healthcare innovation.</p></div></div>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://www.gurufocus.com/news/2655447/cathie-woods-ark-snaps-up-tempus-ai-shares-despite-revenue-miss-and-market-selloff\">GuruFocus</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARKK","symbol_name":"ARK Innovation ETF","start_time":0,"source_url":"https://www.gurufocus.com/news/2655447/cathie-woods-ark-snaps-up-tempus-ai-shares-despite-revenue-miss-and-market-selloff","article_id":"2503284165","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503284165","pubTimestamp":1736851591,"columns":[],"sourceInfo":{"source_id":"gurufocus_highlight","name":"GuruFocus"},"weMediaInfo":null,"summary":"Cathie Wood's ARK Investment Management adds to its stake in Tempus AI  after the stock tumbled nearly 14% on Monday, January 13 4:00 PM ET. The company announces preliminary fourth-quarter revenue projections that fall short of expectations, shaking investor confidence.Tempus AI predicts $200 million in revenue for the quarter, missing analysts' estimates of $205.7 million. Even so, the number shows a 35% jump from the same period last year. CEO Eric Lefkofsky highlights strong growth in genomics revenue, up 30%, and data and services revenue, which climbs 45%. For the full year, revenue climbs 30% to approximately $693 million.ARK's Genomic Revolution ETF  snaps up 379,000 shares during the sell-off, bringing its total holding in Tempus AI to over $47 million. The position now accounts for 4.08% of the fund's portfolio. Other top names in the fund include Twist Bioscience , Recursion Pharmaceuticals , and Crispr Therapeutics .The purchase shows ARK's confidence in Tempus AI's potenti","collect":0,"end_time":0,"defaultTopTitle":"gurufocus.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ARKK":"ARK Innovation ETF","TEM":"Tempus AI"},"translate_title":"尽管营收未达预期且市场抛售，凯西·伍德(Cathie Wood)的方舟仍抢购Tempus AI股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARKK":1,"TEM":1},"content_text":"Cathie Wood's ARK Investment Management adds to its stake in Tempus AI (TEM, Financial) after the stock tumbled nearly 14% on Monday, January 13 4:00 PM ET. The company announces preliminary fourth-quarter revenue projections that fall short of expectations, shaking investor confidence.Tempus AI predicts $200 million in revenue for the quarter, missing analysts' estimates of $205.7 million. Even so, the number shows a 35% jump from the same period last year. CEO Eric Lefkofsky highlights strong growth in genomics revenue, up 30%, and data and services revenue, which climbs 45%. For the full year, revenue climbs 30% to approximately $693 million.ARK's Genomic Revolution ETF (ARKG, Financial) snaps up 379,000 shares during the sell-off, bringing its total holding in Tempus AI to over $47 million. The position now accounts for 4.08% of the fund's portfolio. Other top names in the fund include Twist Bioscience (TWST, Financial), Recursion Pharmaceuticals (RXRX, Financial), and Crispr Therapeutics (CRSP, Financial).The purchase shows ARK's confidence in Tempus AI's potential as a leader in genomics and AI-driven healthcare innovation.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}